Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

624 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting.
Bettelli S, Marcheselli R, Pozzi S, Marcheselli L, Papotti R, Forti E, Cox MCC, Di Napoli A, Tadmor T, Mansueto GR, Musto P, Flenghi L, Quintini M, Galimberti S, Lalinga V, Donati V, Maiorana A, Polliack A, Sacchi S. Bettelli S, et al. Among authors: musto p. Leuk Res. 2021 May;104:106552. doi: 10.1016/j.leukres.2021.106552. Epub 2021 Feb 27. Leuk Res. 2021. PMID: 33689920 No abstract available.
Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature.
Musto P, Scalzulli PR, Terruzzi E, Rossini F, Iacopino P, Messina G, Guariglia R, Pietrantuono G, Villani O, D'Auria F, Falcone A, Sanpaolo G, Valvano MR, Pogliani EM, Morabito F. Musto P, et al. Leuk Res. 2007 Nov;31(11):1487-93. doi: 10.1016/j.leukres.2007.01.008. Epub 2007 Feb 23. Leuk Res. 2007. PMID: 17320951
Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients.
Pozzi S, Marcheselli R, Sacchi S, Baldini L, Angrilli F, Pennese E, Quarta G, Stelitano C, Caparotti G, Luminari S, Musto P, Natale D, Broglia C, Cuoghi A, Dini D, Di Tonno P, Leonardi G, Pianezze G, Pitini V, Polimeno G, Ponchio L, Masini L, Musso M, Spriano M, Pollastri G; Gruppo Italiano Studio Linfomi. Pozzi S, et al. Among authors: musto p. Leuk Lymphoma. 2007 Jan;48(1):56-64. doi: 10.1080/10428190600977690. Leuk Lymphoma. 2007. PMID: 17325848
Role of thalidomide in previously untreated patients with multiple myeloma.
Musto P, D'Auria F, Pietrantuono G, Bringhen S, Morabito F, Di Raimondo F, Pozzi S, Sacchi S, Boccadoro M, Palumbo A; Gruppo Italiano Malatte Ematologiche dell'Adulto Multiple Myeloma Working Party; Italian Myeloma Network and Gruppo Italiano Studio Linfomi. Musto P, et al. Expert Rev Anticancer Ther. 2008 Oct;8(10):1569-80. doi: 10.1586/14737140.8.10.1569. Expert Rev Anticancer Ther. 2008. PMID: 18925849 Review.
ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial.
Federico M, Luminari S, Iannitto E, Polimeno G, Marcheselli L, Montanini A, La Sala A, Merli F, Stelitano C, Pozzi S, Scalone R, Di Renzo N, Musto P, Baldini L, Cervetti G, Angrilli F, Mazza P, Brugiatelli M, Gobbi PG; HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Federico M, et al. Among authors: musto p. J Clin Oncol. 2009 Feb 10;27(5):805-11. doi: 10.1200/JCO.2008.17.0910. Epub 2009 Jan 5. J Clin Oncol. 2009. PMID: 19124807 Clinical Trial.
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Morabito F, Gentile M, Ciolli S, Petrucci MT, Galimberti S, Mele G, Casulli AF, Mannina D, Piro E, Pinotti G, Palmieri S, Catalano L, Callea V, Offidani M, Musto P, Bringhen S, Baldini L, Tosi P, Di Raimondo F, Boccadoro M, Palumbo A, Cavo M. Morabito F, et al. Among authors: musto p. Eur J Haematol. 2010 Mar;84(3):223-8. doi: 10.1111/j.1600-0609.2009.01385.x. Epub 2009 Nov 23. Eur J Haematol. 2010. PMID: 19930441
Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes.
Musto P, Villani O, Martorelli MC, Pietrantuono G, Guariglia R, Mansueto G, D'Auria F, Grieco V, Bianchino G, Sparano A, Zonno A, Lerose R, Sanpaolo G, Falcone A. Musto P, et al. Leuk Res. 2010 Aug;34(8):981-5. doi: 10.1016/j.leukres.2009.10.022. Epub 2009 Nov 20. Leuk Res. 2010. PMID: 19931907
624 results